



Design, Synthesis and Evaluation of coumarin derivatives as antimicrobial activity

Divya pandey,* Dr Niharika Gokhale, Dr P.S Raghu

Oriental college of pharmacy, Oriental University Indore

ABSTRACT

Coumarin exhibit a wide range of activities like antimicrobial,antiviral,antifungal,anti-inflammatory activity, anticancer, antimalarial It is a group of organic compound which contain aromatic ring and a pyrone nucleus Coumarins name has been derived from 'Coumarou', the vernacular call of tonka bean (*Dipteryx odorata* Willd, Fabaceae), from which coumarin, it became remote in 1820. Coumarin or 2H-chromen-2-one is a fragrant organic chemical compound with formulation $C_9H_6O_2$. Its molecule can be defined as a benzene molecule Present study includes synthesis of various analogues of coumarin and their potential for anti-microbial activity. Present work emphasizes on Design and synthesis of coumarin derivatives, Characterization of synthesized coumarin derivatives, Evaluation of synthesized compounds for anti-microbial activity.

KEYWORD: vernacular cell, pyrone, coumarin derivatives, *dipteryx odorata*, antimicrobial

INTRODUCTION

Coumarins name has been derived from 'Coumarou', the vernacular call of tonka bean (*Dipteryx odorata* Willd, Fabaceae), from which coumarin, it became remote in 1820. Coumarin or 2H-chromen-2-one is a fragrant organic chemical compound with formulation $C_9H_6O_2$. Its molecule can be defined as a benzene molecule, with two adjoining hydrogen atoms mostly replaced by using a lactone-like chain - $(CH)=CH-(C=O)-O-$, forming a 2nd 6-membered heterocycle that usually shares two carbons with the benzene ring. It may be located in the benzopyrone chemical category, and also as lactone.¹ Coumarin is a crystalline and colourless solid with a candy smell similar to the fragrance of vanilla and a bitter flavor.² It is present in number of plants, wherein it could also function as a chemical defense against the predators. Where it inhibits the synthesis of vitamin K, a similar compound is used in the prescriptions is warfarin drug as an anticoagulant, which inhibits blood clot formation, deep vein thrombosis, and pulmonary embolism There are four main coumarin sub-types:⁵⁻⁷

Simple coumarins, Furanocoumarins, Pyranocoumarins and Pyrone-substituted coumarin. The

Coumarins was first isolated in 1822 and then synthesized in 1868. Food and Drug Administration banned them in 1950s as they were suspected and categorised as category 1 hepatotoxin and carcinogen, this data was based on the test performed with animal. However, this could require a revision until the next animal records were received. Numbers of coumarin derivatives were supposed to possess tumouristatic, immune-stimulatory and anticoagulant activities.

MATERIAL AND METHOD


CHEMICALS AND INSTRUMENTS

The chemicals which are used in this are 2-oxo-2H-1-benzopyran-3-carboxylic acid, Sulfuric acid, Tetrahydrofuran (THF), Nitric acid, Methanol, Diethyl ether, Dichloromethane, Triethylamine, N, N-dimethylformamide, Hexanes, Palladium on Carbon (Pd/C), Hydrochloric Acid, Sodium Sulphate, Acetyl chloride, 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5b]pyridinium 3-oxidhexafluorophosphate, Hexafluorophosphate Azabenzotriazole Tetramethyl Uronium (HATU)

The IR Spectra of compounds recorded. The ¹H NMR of compounds is recorded and The evaluation of synthesized compounds has done by the Agar diffusion method. Agar diffusion method is of three types; Agar cup method, Paper disc method and Agar ditch method. In present work, Agar cup method was used. Tobramycin was used as reference drugs.

1 Series 1: 3-acetyl-6-(substituted amino)-2H-chromen-2-one derivatives


Step- 1



Synthesis of 3-acetyl-6-nitro-2H-chromen-2-one (2): A mixture of 3-acetyl coumarin **1** (0.188 gm, 1 mmole) and concentrated sulphuric acid (1.10 ml) was stirred at 0 °C for 15 minutes. Then a mixture of concentrated nitric acid (0.06 ml, d 1.4) and sulphuric acid (0.2 ml, 98%) was added. The temperature was kept at 0-5 °C during the period of addition, and the mixture was then continuously stirred for 2 hours at 5 °C. Then the mixture was poured into a conical flask contained 25 ml of an ice water. Solid precipitated out of the water layer, filtered and dried, then purified by silica gel column chromatography (petroleum ether/benzene 1:1 v/v) to isolate the compound 3-acetyl-6-nitro-2H-chromen-2-one **2** (yield 79%).


¹H NMR (400 MHz, DMSO-*d*₆) : δ 2.45 (3H, s), 7.44 (1H, dd, *J* = 7.9, 0.4 Hz), 8.51 (1H, dd, *J* = 7.9, 1.9 Hz), 8.78 (1H, s), 8.84 (1H, dd, *J* = 1.9, 0.4 Hz). MS (ESI) calcd for C₁₈H₁₃NO₄ [M+1]⁺ 308.08, found m/z

308.10

Step-2

4.2 Synthesis of 3-acetyl-6-amino-2H-chromen-2-one (3): A mixture of compound **2** 3-acetyl-6-nitro-2H-chromen-2-one (0.233 g, 1 mmol 3.14 gm, 0.01 mole) with Iron powder (0.296 g), concentrated hydrochloric acid (1.11 ml) and ethanol (10 ml) was refluxed for 6 hours. Then cool the reaction mixture, the precipitate formed was filtered off, washed with a copious amount of water and dried. Crude product was purified by recrystallization with ethanol and compound 3-acetyl-6-amino-2H-chromen-2-one **3** formed yield (72 %).

¹H NMR: δ 2.44 (3H, s), 6.77 (1H, dd, $J = 8.5, 1.7$ Hz), 7.20 (1H, dd, $J = 8.5, 0.5$ Hz), 7.51 (1H, dd, $J = 1.7, 0.5$ Hz), 8.65 (1H, s). MS (ESI) calcd for C₁₁H₉NO₃ [M+1]⁺ 226.04, found m/z 226.17


Step-3 Synthesis of Coumarin derivatives through the various benzoic acids**Synthesis of Compound- 4a**

Synthesis of N-(3-acetyl-2-oxo-2H-chromen-6-yl)benzamide (4a): To a mixture of 3-acetyl-6-aminocoumarin (0.203 g, 1 mmol) and benzoic acid (0.122 g, 1 mmol) was added thionyl chloride (0.141 g, 1.2 mmol, 1.2 equiv) and benzene (1.5 ml) and refluxed for 2 hr. Then the mixture was poured into a conical flask contained 25 ml of an ice water. Solid precipitated out of the water layer, filtered and dissolved in 1.25 ml of 2N sodium hydroxide solution and filtered again. The solution was acidified with 2N hydrochloric acid, filtered by Buchner funnel and washed with a copious amount of cold water and concentrated in vacuo to give the crude product which was purified by re-crystallization from

ethanol and gave compound *N*-(3-acetyl-2-oxo-2H-chromen-6-yl)benzamide (**4a**) (yield 65%).

3314(N-H str), 3082 (C-H str), 3056(aromatic C-H str), 1744 (lactone ester), 1693 (CONH amide), 1680 (C=O str), 1537 (C=C aromatic), 1424 (C-O-C str). $^1\text{H NMR}$: δ 2.51 (3H, s), 8.32-8.49 (2H, 7.46 (dd, $J = 8.6, 1.5$ Hz), 7.43 (dd, $J = 8.6, 0.5$ Hz)), 7.53-7.63 (3H, m), 7.58 (dd, $J = 8.5, 7.5$ Hz)), 7.64 (1H, dd, $J = 1.5, 0.5$ Hz), 8.00 (2H, dd, $J = 8.5, 1.9$ Hz), 8.71 (1H, s). MS (ESI) calcd for $\text{C}_{18}\text{H}_{13}\text{NO}_4$ $[\text{M}+\text{Na}]^+$ 330.07, found m/z 330.18.

Synthesis of Compound- 4b




Synthesis of

***N*-(3-acetyl-2-oxo-2H-chromen-6-yl)-4-chlorobenzamide (4b)**: To a mixture of 3-acetyl-6-aminocoumarin (0.203 g, 1 mmol) and 4-chlorobenzoic acid (0.156 g, 1 mmol) was added thionyl chloride (0.141 g, 1.2 mmol, 1.2 equiv) and benzene (1.5 ml) and refluxed for 2 hr. Then the mixture was poured into a conical flask contained 25 ml of an ice water. Solid precipitated out of the water layer, filtered and dissolved in 1.25 ml of 2N sodium hydroxide solution and filtered again. The solution was acidified with 2N hydrochloric acid, filtered by Buchner funnel and washed with a copious amount of cold water and concentrated in vacuo to give the crude product which was purified by re-crystallization from ethanol and gave compound *N*-(3-acetyl-2-oxo-2H-chromen-6-yl)-4-chlorobenzamide (**4b**) (yield 68%).

3320(N-H str), 3050 (C-H str), 3067(aromatic C-H str), 1766 (lactone ester), 1681 (CONH amide), 1686 (C=O str), 1528 (C=C aromatic), 1421 (C-O-C str), 800 (C-Cl). $^1\text{H NMR}$: δ 2.54 (3H, s), 8.63 (2H, s), 7.43 (dd, $J = 8.6, 0.5$ Hz)), 7.53 (2H, dd, $J = 8.7, 1.4$ Hz), 7.64 (1H, dd, $J = 1.5, 0.5$ Hz), 7.75 (2H, dd, $J = 8.7, 1.8$ Hz), 8.71 (1H, s). MS (ESI) calcd for $\text{C}_{18}\text{H}_{12}\text{ClNO}_4$ $[\text{M}+\text{Na}]^+$ 364.03, found m/z 364.19

Synthesis of Compound- 4c




Synthesis of *N*-(3-acetyl-2-oxo-2H-chromen-6-yl)-4-fluorobenzamide (4c): To a mixture of 3-acetyl-6-aminocoumarin (0.203 g, 1 mmol) and 4-fluorobenzoic acid (0.140 g, 1 mmol) was added thionyl chloride (0.141 g, 1.2 mmol, 1.2 equiv) and benzene (1.5 ml) and refluxed for 2 hr. Then the mixture was poured into a conical flask contained 25 ml of an ice water. Solid precipitated out of the water

layer, filtered and dissolved in 1.25 ml of 2N sodium hydroxide solution and filtered again. The solution was acidified with 2N hydrochloric acid, filtered by Buchner funnel and washed with a copious amount of cold water and concentrated in vacuo to give the crude product which was purified by re-crystallization from ethanol and gave compound *N*-(3-acetyl-2-oxo-2H-chromen-6-yl)-4-fluorobenzamide (**4c**) (yield 71%).

3330(N-H str), 3056 (C-H str), 3047(aromatic C-H str), 1746 (lactone ester), 1689 (CONH amide), 1680 (C=O str), 1538 (C=C aromatic), 1429 (C-O-C str), 1155 (C-F). ¹H NMR: δ 2.16 (3H, s), 7.67-7.70 (4H, 7.46 (dd, *J* = 8.6, 1.5 Hz), 7.47 (dd, *J* = 8.7, 1.1 Hz), 7.43 (dd, *J* = 8.6, 0.5 Hz), 7.64 (1H, dd, *J* = 1.5, 0.5 Hz), 7.90 (2H, dd, *J* = 8.7, 1.8 Hz), 8.71 (1H, s). MS (ESI) calcd for C₁₈H₁₂FNO₄ [M+Na]⁺ 348.06, found m/z 348.22


Synthesis of Compound- 4d



Synthesis of *N*-(3-acetyl-2-oxo-2H-chromen-6-yl)-4-nitrobenzamide (4d): To a mixture of 3-acetyl-6-aminocoumarin (0.203 g, 1 mmol) and 4-nitrobenzoic acid (0.167 g, 1 mmol) was added thionyl chloride (0.141 g, 1.2 mmol, 1.2 equiv) and benzene (1.5 ml) and refluxed for 2 hr. Then the mixture was poured into a conical flask contained 25 ml of an ice water. Solid precipitated out of the water layer, filtered and dissolved in 1.25 ml of 2N sodium hydroxide solution and filtered again. The solution was acidified with 2N hydrochloric acid, filtered by Buchner funnel and washed with a copious amount of cold water and concentrated in vacuo to give the crude product which was purified by re-crystallization from ethanol and gave compound *N*-(3-acetyl-2-oxo-2H-chromen-6-yl)-4-nitrobenzamide (**4d**) (yield 66%).

3342 (N-H str), 3060 (C-H str), 3052 (aromatic C-H str), 1748 (lactone ester), 1692 (CONH amide), 1689 (C=O str), 1530 (C=C aromatic), 1516 (NO₂), 1436 (C-O-C str), 1355 (NO₂). ¹H NMR: δ 2.46 (3H, s), 8.30-8.19 (2H, 7.46 (dd, *J* = 8.6, 1.5 Hz), 7.43 (dd, *J* = 8.6, 0.5 Hz)), 7.64 (1H, dd, *J* = 1.5, 0.5 Hz), 7.89 (2H, dd, *J* = 8.6, 1.4 Hz), 8.14 (2H, dd, *J* = 8.6, 1.8 Hz), 8.71 (1H, s). MS (ESI) calcd for C₁₈H₁₂N₂O₆ [M+Na]⁺ 375.05, found m/z 375.23

Synthesis of Compound- 4e




Synthesis of *N*-(3-acetyl-2-oxo-2H-chromen-6-yl)-4-aminobenzamide (4e): To a mixture of 3-acetyl-6-aminocoumarin (0.203 g, 1 mmol) and 4-aminobenzoic acid (0.137 g, 1 mmol) was added thionyl chloride (0.141 g, 1.2 mmol, 1.2 equiv) and benzene (1.5 ml) and refluxed for 2 hr. Then the mixture was poured into a conical flask contained 25 ml of an ice water. Solid precipitated out of the water layer, filtered and dissolved in 1.25 ml of 2N sodium hydroxide solution and filtered again. The solution was acidified with 2N hydrochloric acid, filtered by Buchner funnel and washed with a copious amount of cold water and concentrated in vacuo to give the crude product which was purified by re-crystallization from ethanol and gave compound *N*-(3-acetyl-2-oxo-2H-chromen-6-yl)-4-aminobenzamide (**4e**) (yield 64%).

3352 (N-H str), 3053 (C-H str), 3050 (aromatic C-H str), 1745 (lactone ester), 1686 (CONH amide), 1678 (C=O str), 1605 (NH₂ bending), 1537 (C=C aromatic), 1436 (C-O-C str). ¹H NMR: δ 2.96 (3H, s), 8.87 (2H, dd, *J* = 8.6, 1.1 Hz), 7.40-7.48 (2H, dd, *J* = 8.6, 1.5 Hz), 7.42 (dd, *J* = 8.6, 0.5 Hz), 7.55 (2H, dd, *J* = 8.6, 1.7 Hz), 7.64 (1H, dd, *J* = 1.5, 0.5 Hz), 8.71 (1H, s). MS (ESI) calcd for C₁₈H₁₄N₂O₄ [M+Na]⁺ 345.08, found *m/z* 345.30

Series 2: Hydrolysis of Compounds 4 derivatives


Synthesis of Compound- 5a



Synthesis of 6-benzamido-2-oxo-2H-chromene-3-carboxylic acid (5a): The previously synthesized molecule of *N*-(3-acetyl-2-oxo-2H-chromen-6-yl)benzamide (**4a**) (0.307 g, 1 mmol) was mixed with mixtures of water (1.5 ml), methanol (1.5 ml) and THF (1.5 ml) then added LiOH monohydrate (1.13 g, 3.69 mmol) and reaction mixture were stirred at RT for 6 hr. When all starting materials were consumed reaction mass acidified with 3M HCl solution until 2.0 pH was reached and extracted with ethyl acetate. Organic layer was dried over sodium sulfate and distilled out under vacuum to get crude product which was purified by silica gel chromatography (hexane: ethylacetate 8:2 v/v) and gave compound 6-benzamido-2-oxo-2H-chromene-3-carboxylic acid (**5a**) (yield 58%).

3314(N-H str), 3056(aromatic C-H str), 2841(carboxylic acid OH str), 1744 (lactone ester), 1693 (CONH amide), 1537 (C=C aromatic), 1424 (C-O-C str). $^1\text{H NMR}$: δ 7.40-7.48 (2H, 8.10(dd, J = 8.6, 1.5 Hz), 7.42 (dd, J = 8.6, 0.5 Hz), 7.53-7.63 (3H, m), 7.58 (dd, J = 8.5, 7.5 Hz), 7.64 (1H, dd, J = 1.5, 0.5 Hz), 8.00 (2H, dd, J = 8.5, 1.9 Hz), 8.81 (1H, s). MS (ESI) calcd for $\text{C}_{17}\text{H}_{11}\text{NO}_5$ $[\text{M}+1]^+$ 310.07, found m/z 310.18


Synthesis of Compound- 5b



Synthesis of 6-(4-chlorobenzamido)-2-oxo-2H-chromene-3-carboxylic acid (5b): The previously synthesized molecule of *N*-(3-acetyl-2-oxo-2H-chromen-6-yl)-4-chlorobenzamide (**4b**) (0.341 g, 1 mmol) was mixed with mixtures of water (1.5 ml), methanol (1.5 ml) and THF (1.5 ml) then added LiOH monohydrate (1.26 g, 3.69 mmol) and reaction mixture were stirred at rt for 6 hr. When all starting materials were consumed reaction mass acidified with 3M HCl solution until 2.0 pH was reached and extracted with ethyl acetate. Organic layer was dried over sodium sulfate and distilled out under vacuum to get crude product which was purified by silica gel chromatography (hexane: ethylacetate 8:2 v/v) and gave compound 6-(4-chlorobenzamido)-2-oxo-2H-chromene-3-carboxylic acid (**5b**) (yield 56 %)

3391 (Amide-NH), 3055 (Aromatic-CH), 2596 (Carboxylic acid-OH) 1760 (lactone ester), 1669 (Amide CO), 1618(Amide-NH), 1573 (Aromatic C-C), 800 (C-Cl). $^1\text{H NMR}$: δ 8.40-8.48 (2H, 7.45 (dd, J = 8.6, 1.5 Hz), 7.42 (dd, J = 8.6, 0.5 Hz), 7.53 (2H, dd, J = 8.7, 1.4 Hz), 7.64 (1H, dd, J = 1.5, 0.5 Hz), 7.71 (2H, dd, J = 8.7, 1.8 Hz), 8.81 (1H, s). MS (ESI) calcd for $\text{C}_{17}\text{H}_{10}\text{ClNO}_5$ $[\text{M}+1]^+$ 344.03, found m/z 344.22

Synthesis of Compound- 5c




Synthesis of 6-(4-fluorobenzamido)-2-oxo-2H-chromene-3-carboxylic acid (5c): The previously synthesized molecule of *N*-(3-acetyl-2-oxo-2H-chromen-6-yl)-4-fluorobenzamide (**4c**) (0.325 g, 1 mmol) was mixed with mixtures of water (1.5 ml), methanol (1.5 ml) and THF (1.5 ml) then added LiOH monohydrate (1.20 g, 3.69 mmol) and reaction mixture were stirred at room temp for 6 hr. When all starting materials were consumed reaction mass acidified with 3M HCl solution until 2.0 pH was reached and extracted with ethyl acetate. Organic layer was dried over sodium sulfate and distilled out under vacuum to get crude product which was purified by silica gel chromatography

(hexane:ethylacetate 8:2 v/v) and gave compound 6-(4-fluorobenzamido)-2-oxo-2H-chromene-3-carboxylic acid (**5c**) (yield 61%).

3387 (Amide-NH), 3050 (Aromatic-CH), 2591 (Carboxylic acid-OH) 1765 (lactone ester), 1672 (Amide CO), 1622(Amide-NH), 1567 (Aromatic C-C), 1155 (C-F). $^1\text{H NMR}$: δ 8.10-7.90 (4H, 7.45 (dd, $J = 8.6, 1.5$ Hz), 7.47 (dd, $J = 8.7, 1.1$ Hz), 7.42 (dd, $J = 8.6, 0.5$ Hz), 7.64 (1H, dd, $J = 1.5, 0.5$ Hz), 7.90 (2H, dd, $J = 8.7, 1.8$ Hz), 8.81 (1H, s). MS (ESI) calcd for $\text{C}_{17}\text{H}_{10}\text{FNO}_5$ $[\text{M}+1]^+$ 328.06, found m/z 328.40


Synthesis of Compound- 5d



Synthesis of 6-(4-nitrobenzamido)-2-oxo-2H-chromene-3-carboxylic acid (5d): The previously synthesized molecule of *N*-(3-acetyl-2-oxo-2H-chromen-6-yl)-4-nitrobenzamide (**4d**) (0.352 g, 1 mmol) was mixed with mixtures of water (1.5 ml), methanol (1.5 ml) and THF (1.5 ml) then added LiOH monohydrate (1.30 g, 3.69 mmol) and reaction mixture were stirred at room temp for 6 hr. When all starting materials were consumed reaction mass acidified with 3M HCl solution until 2.0 pH was reached and extracted with ethyl acetate. Organic layer was dried over sodium sulfate and distilled out under vacuum to get crude product which was purified by silica gel chromatography (hexane: ethylacetate 8:2 v/v) and gave compound 6-(4-nitrobenzamido)-2-oxo-2H-chromene-3-carboxylic acid (**5d**) (yield- 57%).

3390(Amide-NH), 3058 (Aromatic-CH), 2591 (Carboxylic acid-OH) 1756 (lactone ester), 1678 (Amide CO), 1631 (Amide-NH), 1561 (Aromatic C-C), 1520 (NO_2), 1361 (NO_2). $^1\text{H NMR}$: δ 7.40-7.49 (2H, dd, $J = 8.6, 1.4$ Hz), 7.43 (dd, $J = 8.6, 0.5$ Hz), 7.64 (1H, dd, $J = 1.4, 0.5$ Hz), 7.89 (2H, dd, $J = 8.6, 1.4$ Hz), 8.14 (2H, dd, $J = 8.6, 1.8$ Hz), 8.81 (1H, s). MS (ESI) calcd for $\text{C}_{17}\text{H}_{10}\text{N}_2\text{O}_7$ $[\text{M}+1]^+$ 355.05, found m/z 355.34

Synthesis of Compound- 5e



Synthesis of 6-(4-aminobenzamido)-2-oxo-2H-chromene-3-carboxylic acid (5e): The previously synthesized molecule of *N*-(3-acetyl-2-oxo-2H-chromen-6-yl)-4-aminobenzamide (**4e**) (0.322 g, 1 mmol) was mixed with mixtures of water (1.5 ml), methanol (1.5 ml) and THF (1.5 ml) then added LiOH monohydrate (1.19 g,

3.69 mmol) and reaction mixture were stirred at room temp for 6 hr. When all starting materials were consumed reaction mass acidified with 3M HCl solution until 2.0 pH was reached and extracted with ethyl acetate. Organic layer was dried over sodium sulfate and distilled out under vacume to get crude product which was purified by silica gel chromatography (hexane: ethylacetate 8:2 v/v) and gave compound 6-(4-aminobenzamido)-2-oxo-2H-chromene-3-carboxylic acid (**5e**) (yield-55%).

3384(Amide-NH), 3048 (Aromatic-CH), 2590 (Carboxylic acid-OH) 1751 (lactone ester), 1668 (Amide CO), 1633 (Amide-NH), 1610 (NH₂ bending), 1560 (Aromatic C-C). ¹H NMR: δ 8.39-8.18 (2H, dd, *J* = 8.6, 1.5 Hz), 7.42 (dd, *J* = 8.6, 0.5 Hz), 7.55 (2H, dd, *J* = 8.6, 1.7 Hz), 7.64 (1H, dd, *J* = 1.5, 0.5 Hz), 8.83 (1H, s). MS (ESI) calcd for C₁₇H₁₂N₂O₅ [M+1]⁺ 325.08, found m/z 325.32.

Antimicrobial evaluation

Following bacteria were selected for *in-vitro* study.

- 1). **Gram-positive:** *Bacillus subtilis* ATCC 14579 and *Staphylococcus aureus* ATCC 25923
- 2). **Gram-negative:** *Pseudomonas aeruginosa* ATCC 27853 and *Escherichia coli* ATCC 25922

Culture medium preparation:

Culture medium is prepared by using Peptone (1.0 gm), NaCl (0.5 gm), Meat extracts (0.3 gm) and Agar (2.0 gm). All ingredient except agar was dissolved in distilled water (100 ml) and pH of medium was adjusted to 7.6 then after agar was added to the medium and dispensed in 25 ml quantity in different test tubes. The test tubes were plugged by cotton-wool and sterilized at 121.5°C for 20 minutes.

Antibacterial susceptibility testing: Nutrient agar broth was inoculated with 0.5 ml of culture medium which was 24 hour old and mixed well by shaking before pouring on the sterilized Petri dish (25 ml each). The poured material was allowed to set for some time and then the "cups" was made by punching into the agar surface with a sterile cup borer. Into this "cups" test solution was added by previously sterilized micropipette. The plates were noted. The antibacterial activity of all synthesized compounds was studied at 1000 ppm concentration *in-vitro* and calculated in percentage (%) of inhibition, shown in Table 1 and 2.

The percentage inhibition for bacteria was calculated after five days using the given formula.

$$\text{Percentage of inhibition} = 100 \left(1 - \frac{Y}{X} \right)$$

Where

X = Area of colony in control plate.

Y = Area of colony in test plate.

*The percentage (%) data are shown in **table 6 and 7** as follows;*

- (+) = Small clearing zone (<50%), slightly active,
- (++) = Medium clearing zone (51-55%), moderately active,
- (+++) = Large clearing zone (56-60%), highly active and,
- (+++++) = Very large clearing zone (>60%), very high activity.

Table 6: Antibacterial activity of compounds (4a-e)

Compounds (4a-e)	% Zone of Inhibition			
	Gram +Ve		Gram -Ve	
	<i>Bacillus Subtilis</i>	<i>Staphylococcus Aureus</i>	<i>Pseudomonas aeruginosa</i>	<i>E-Coli</i>
4a	+	++	+	++
4b	++	+	++	++
4c	+++	+	+++	++
4d	++	+++	++	+++
4e	++	++	++	++
Tobramycin	+++++	+++	+++++	+++++

Table 7: Antibacterial activity of compounds (5a-e)

Compounds (5a-e)	% Zone of Inhibition			
	Gram +Ve		Gram -Ve	
	<i>Bacillus subtilis</i>	<i>Staphylococcus Aureus</i>	<i>Pseudomonas aeruginosa</i>	<i>E-Coli</i>
5a	++	++	++	++
5b	+	+	++	++
5c	++	+++++	+++	+++++
5d	+++++	+++	+++++	+++
5e	++	+++	++	++
Tobramycin	+++++	+++	+++++	+++++

The compounds tested for antibacterial activity show percentage (%) of zone of inhibition of bacterial growth of Gram-positive and Gram-negative bacteria. For antibacterial study, 4 compounds of **Series 1 (4a-e)** and 4 compounds of **Series 2 (5a-e)** were tested for bacterial strain Gram-positive bacterial strains *B.subtilis* and *S.aureus* and Gram-negative bacterial strains *P. aeruginosa*, and *E.Coli*.

In **Series 1** Compound **4d** were found promising activity against bacterial strain *S.aureus* and *E.Coli* In **Series 2**, compound **5d** were found promising activity against bacterial strain *B.subtilis* and *P. aeruginosa*

CONCLUSION:

The compound 6-(4-nitrobenzamido)-2-oxo-2H-chromene-3-carboxylic acid, N-(3-acetyl-2-oxo-2H-chromen-6-yl)-4-nitrobenzamide shows maximum activity as antimicrobial and further research needed

to establish the molecular mechanism.

REFERENCES

1. Chen CH, Fox JL, Duarte FJ, Ehrlich JJ. Lasing characteristics of new coumarin-analog dyes: broadband and narrow-linewidth performance. *Applied optics*. 1988 Feb 1;27(3):443-5.
2. Chen CH, Fox JL, Duarte FJ, Ehrlich JJ. Lasing characteristics of new coumarin-analog dyes: broadband and narrow-linewidth performance. *Applied optics*. 1988 Feb 1;27(3):443-5.
3. Duarte FJ, Liao LS, Vaeth KM, Miller AM. Widely tunable green laser emission using the coumarin 545 tetramethyl dye as the gain medium. *Journal of Optics A: Pure and Applied Optics*. 2006 Jan 13;8(2):172.
4. Agarwal R. Synthesis & biological screening of some novel coumarin derivatives. *Biochem Pharmacol*. 2000; 6: 1042-1051.
5. Ojala T. Biological screening of plant coumarins. 2001;1-58
6. Jain PK, Joshi H. Coumarin: chemical and pharmacological profile. *Journal of Applied Pharmaceutical Science*. 2012;2(6):236-40.
7. Hoult JR, Payá M. Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential. *General pharmacology: The vascular system*. 1996 Jun 1;27(4):713-22.
8. Bourgaud F, Hehn A, Larbat R, Doerper S, Gontier E, Kellner S, Matern U. Biosynthesis of coumarins in plants: a major pathway still to be unravelled for cytochrome P450 enzymes. *Phytochemistry Reviews*. 2006 Jun 1;5(2-3):293-308.
9. Vialart G, Hehn A, Olry A, Ito K, Krieger C, Larbat R, Paris C, Shimizu BI, Sugimoto Y, Mizutani M, Bourgaud F. A 2-oxoglutarate-dependent dioxygenase from *Ruta graveolens* L. exhibits p-coumaroyl CoA 2'-hydroxylase activity (C2' H): a missing step in the synthesis of umbelliferone in plants. *The Plant Journal*. 2012 May;70(3):460-70.
10. Larbat R, Hehn A, Hans J, Schneider S, Jugdé H, Schneider B, Matern U, Bourgaud F. Isolation and functional characterization of CYP71AJ4 encoding for the first P450 monooxygenase of angular furanocoumarin biosynthesis. *Journal of Biological Chemistry*. 2009 Feb 20;284(8):4776-85.
11. Shilling WH, Crampton RF, Longland RC. Metabolism of coumarin in man. *Nature*. 1969 Feb;221(5181):664-5.
12. Egan D, O'Kennedy R, Moran E, Cox D, Prosser E, Thornes RD. The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds. *Drug metabolism reviews*. 1990 Jan 1;22(5):503-29.

13. Egan DA, Deasy B, Dempsey E, Smyth MR, O'Kennedy R. Antibody-based approaches to coumarin analysis. *Journal of cancer research and clinical oncology*. 1994 Jan 1;120(1):S28-9.
14. Fentem JH, Fry JR, Whiting DA. o-Hydroxyphenylacetaldehyde: a major novel metabolite of coumarin formed by rat, gerbil and human liver microsomes. *Biochemical and biophysical research communications*. 1991 Aug 30;179(1):197-203.
15. Cohen AJ. Critical review of the toxicology of coumarin with special reference to interspecies differences in metabolism and hepatotoxic response and their significance to man. *Food and cosmetics toxicology*. 1979 Jan 1;17(3):277-89.
16. Poumale HM, Hamm R, Zang Y, Shiono Y, Kuete V. Coumarins and related compounds from the medicinal plants of Africa. In *Medicinal plant research in Africa 2013* Jan 1 (pp. 261-300).
17. Shaikh S, Shakil S, M Abuzenadah A, Michael Roberts P, Mushtaq G, Amjad Kamal M. Nanobiotechnological approaches against multidrug resistant bacterial pathogens: An update. *Current drug metabolism*. 2015 Jun 1;16(5):362-70.
18. Adelia C. Bovell-Benjamin, Jerry Roberts, *Naturally Occurring Toxicants: Presence in Selected Commonly Consumed Fruits, Regulating Safety of Traditional and Ethnic Foods*, 2016; 247-282
19. Minke Reuvers, *Anticoagulant and fibrinolytic drugs, Drugs During Pregnancy and Lactation*, Academic Press 2007; 237-253
20. Tarik Bor, Sulaiman O. Aljaloud Rabin Gyawali Salam A. Ibrahim, *Antimicrobials from herbs, spices, and plants, Fruits, Vegetables, and Herbs Bioactive Foods in Health Promotion 2016*; 551-57
21. Smyth T, Ramachandran VN, Smyth WF. A study of the antimicrobial activity of selected naturally occurring and synthetic coumarins. *International journal of antimicrobial agents*. 2009 May 1;33(5):421-6
22. Hervé Martial Poumale Poumale, Victor Kuete, *Coumarins and Related Compounds from the Medicinal Plants of Africa, Medicinal Plant Research in Africa*, 2013; 261-300.
23. Tenover FC. Mechanisms of antimicrobial resistance in bacteria. *Am. J. Med.* 2006; 34:64-73
24. Adelia C. Bovell-Benjamin, Jerry Roberts, *Naturally Occurring Toxicants: Presence in Selected Commonly Consumed Fruits, Regulating Safety of Traditional and Ethnic Foods*, 2016; 247-282
25. Naithani R, Huma LC, Holland LE, Shukla D, McCormick DL, Mehta RG, Moriarty RM. Antiviral activity of phytochemicals: a comprehensive review. *Mini reviews in medicinal chemistry*. 2008 Oct 1;8(11):1106-33.
26. Tataringa G, Zbancioc AM. Coumarin Derivatives with Antimicrobial and Antioxidant Activities. In *Applications of Coumarin Derivatives 2019* Jul 27. IntechOpen.
27. Al-Majedy YK, Kadhum AA, Al-Amiery AA, Mohamad AB. Coumarins: the antimicrobial agents.

- Systematic Reviews in Pharmacy. 2017;8(1):62.
28. Hassan MZ, Osman H, Ali MA, Ahsan MJ. Therapeutic potential of coumarins as antiviral agents. *European journal of medicinal chemistry*. 2016 Nov 10;123:236-55.
29. Prusty JS, Kumar A. Coumarins: antifungal effectiveness and future therapeutic scope. *Molecular diversity*. 2019 Sep 13;1-7.
30. Venugopala KN, Rashmi V, Odhav B. Review on natural coumarin lead compounds for their pharmacological activity. *BioMed research international*. 2013; 2013, 1-14.
31. Hirsch AM, Longeon A, Guyot M. Fraxin and esculin: two coumarins specific to *Actinidia chinensis* and *A. deliciosa* (kiwifruit). *Biochemical systematics and ecology*. 2002 Jan 1;30(1):55-60.
32. Loukopoulos V, Meier C, Gerding H. Hemorrhagic complications after intravitreal injections of ranibizumab in patients under coumarin-type anticoagulation. *Klinische Monatsblätter für Augenheilkunde*. 2010 Apr;227(04):289-91.
33. Govindan SV, Moon SJ, Goldenberg DM, inventors; Immunomedics Inc, assignee. Immunoconjugates with an intracellularly-cleavable linkage. United States patent US 8,080,250. 2011 Dec 20.
34. Bronikowska J, Szliszka E, Jaworska D, Czuba ZP, Krol W. The coumarin psoralidin enhances anticancer effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). *Molecules*. 2012 Jun;17(6):6449-64.
35. Emami S, Dadashpour S. Current developments of coumarin-based anti-cancer agents in medicinal chemistry. *European Journal of Medicinal Chemistry*. 2015 Sep 18;102:611-30.
36. Abd-El-Aziz AS, Mohamed HM, Mohammed S, Zahid S, Ata A, Bedair AH, El-Agrody AM, Harvey PD. Synthesis of novel coumarin and benzocoumarin derivatives and their biological and photophysical studies. *Journal of Heterocyclic Chemistry*. 2007 Nov;44(6):1287-301.
37. Govori S, Kaljaj V, Rapic V, Kaljaj L, Đakovic S. Synthesis and structure of some 3, 4-annelated coumarin systems. *Heterocyclic Communications*. 2002;8(2):129-34.
38. Chimenti F, Secci D, Bolasco A, Chimenti P, Granese A, Befani O, Turini P, Alcaro S, Ortuso F. Inhibition of monoamine oxidases by coumarin-3-acyl derivatives: biological
39. Kusanur RA, Kulkarni MV. New 1, 3-dipolar cycloadducts of 3-azidoacetyl coumarins with DMAD and their antimicrobial activity. 2005
40. Göker H, Boykin DW, Yıldız S. Synthesis and potent antimicrobial activity of some novel 2-phenyl or methyl-4H-1-benzopyran-4-ones carrying amidinobenzimidazoles. *Bioorganic & medicinal chemistry*. 2005 Mar 1;13(5):1707-14.
41. Tuncbilek M, Altanlar N. Synthesis of New 3-(Substituted

- Phenacyl)-5-[3'-(4H-4-oxo-1-benzopyran-2-yl)-benzylidene]-2, 4-thiazolidinediones and their Antimicrobial Activity. *Archiv der Pharmazie: An International Journal Pharmaceutical and Medicinal Chemistry*. 2006 Apr;339(4):213-6.
42. Vyas KB, Nimavat KS, Jani GR, Hathi MV. Synthesis and antimicrobial activity of coumarin derivatives metal complexes: an in vitro evaluation. *Orbital: The Electronic Journal of Chemistry*. 2009 Sep 6;1(2):183-92.
43. Ronad PM, Noolvi MN, Sapkal S, Dharbhamulla S, Maddi VS. Synthesis and antimicrobial activity of 7-(2-substituted phenylthiazolidinyl)-benzopyran-2-one derivatives. *European journal of medicinal chemistry*. 2010 Jan 1;45(1):85-9.
44. Chimenti F, Bizzarri B, Bolasco A, Secci D, Chimenti P, Granese A, Carradori S, Rivanera D, Zicari A, Scaltrito MM, Sisto F. Synthesis, selective anti-*Helicobacter pylori* activity, and cytotoxicity of novel N-substituted-2-oxo-2H-1-benzopyran-3-carboxamides. *Bioorganic & medicinal chemistry letters*. 2010 Aug 15;20(16):4922-6.
45. Basanagouda M, Shivashankar K, Kulkarni MV, Rasal VP, Patel H, Mutha SS, Mohite AA. Synthesis and antimicrobial studies on novel sulfonamides containing 4-azidomethyl coumarin. *European journal of medicinal chemistry*. 2010 Mar 1;45(3):1151-7.
46. Shi Y, Zhou CH. Synthesis and evaluation of a class of new coumarin triazole derivatives as potential antimicrobial agents. *Bioorganic & medicinal chemistry letters*. 2011 Feb 1;21(3):956-60.
47. Osman H, Arshad A, Lam CK, Bagley MC. Microwave-assisted synthesis and antioxidant properties of hydrazinyl thiazolyl coumarin derivatives. *Chemistry Central Journal*. 2012 Dec 1;6(1):32.
48. Laxmi SV, Kuarm BS, Rajitha B. Synthesis and antimicrobial activity of coumarin pyrazole pyrimidine 2, 4, 6 (1H, 3H, 5H) triones and thioxopyrimidine 4, 6 (1H, 5H) diones. *Medicinal Chemistry Research*. 2013 Feb 1;22(2):768-74.